Digital Look

Welcome to Digital Look++,
you are not logged in

Valirx (VAL)

Pharma and Biotech

6.15p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (pm)	Pre-tax (pm)	EPS	Dividend
30-Jun-23	Interim	n/a	(1.15p)	(1.03)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-18	n/a	(4.83)	(117.50)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-19	n/a	(2.72)	(4,135.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-20	n/a	(1.54)	(3.81)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	n/a	(1.68)	(2.34)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	n/a	(2.60)	(3.06)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-23	n/a	(2.30)	(2.00)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.